IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas

Debora Martorelli¹, Massimo Guidoboni¹, Valli De Re², Elena Muraro¹, Riccardo Turini², Anna Merlo³, Elisa Pasini¹, Laura Gaggiari², Luca Romagnoli³, Michele Spina³, Roberta Mortarini³, Daniela Gasparotto⁴, Mario Mazzucato⁵, Antonino Carbone⁶, Antonio Rosato⁷, Andrea Anichini⁹, and Riccardo Dolcetti¹

Abstract

Purpose: An increasing set of B-cell non-Hodgkin lymphomas (B-NHL) show a biased usage of IGKV-20 and IGKV-15 immunoglobulin genes, a feature that could be exploited for the development of ready-to-use, broadly applicable cancer vaccines.

Experimental Design: The immunogenic properties of clonal IGKV-20 and IGKV-15 proteins were analyzed with particular focus on their ability to elicit cross-reactive responses against molecularly related IGK proteins expressed by different B-cell lymphoproliferative disorders.

Results: IGK+ lymphoma patients show humoral and T-cell responses to IGKV-20 and IGKV-15 proteins and IGKV3-specific cytotoxic T lymphocytes (CTL) can be easily induced ex vivo. IGKV3-20–specific CTLs cross-react against different IGKV3 proteins, an effect mediated by the presence of 21 shared, sometimes promiscuous, T-cell epitopes, presented by common HLA class I allele products, thus assuring a broad HLA coverage of IGKV3-based vaccines. Many natural epitope variants are carried by IGK light chains expressed by a broad spectrum of B-NHLs and we show that IGKV3-20–specific CTLs cross-react also against several of these variant epitopes. Both humoral and CTL-specific responses were induced by KLH-conjugated IGKV3-20 protein in HLA-A2-transgenic mice and coinjection of IGKV3-20–specific CTLs with IGKV3-20+ or IGKV3-15+ lymphoma cells into SCID mice totally prevented tumor growth, thus confirming the ability of these effectors to mediate efficient and cross-reactive cytotoxic responses also in vivo.

Conclusions: These results provide the rationale to exploit IGKV3 proteins as "off-the-shelf" vaccines for a large fraction of lymphoma patients. Clin Cancer Res; 18(15); 4080–91. ©2012 AACR.

Introduction

Therapeutic vaccines targeting B-cell non-Hodgkin lymphoma (NHL) idiotype (Id) represent a promising approach to improve the clinical control of these malignancies (1, 2). Indeed, immunization with tumor B-cell Id has been associated with induction of lymphoma-specific humoral and cellular responses, molecular remissions, and prolonged progression-free or disease-free survival in several phase I/II studies (1–8). Moreover, 1 of 3 phase III randomized trials carried out so far has shown prolonged remission duration in follicular lymphoma patients in first remission (9). Although the reasons for these diverging results are still a matter of debate, differences in the methods used for vaccine production could have accounted for the different outcomes observed. In all these studies, in fact, idiotypic immunoglobulins (Ig) were produced in vitro from each patient using different protocols, which usually imply considerable efforts and costs (1, 2). Therefore, there is the need to develop Id vaccines that can be more easily manufactured and applicable to a larger number of patients (10). Indeed, availability of broadly usable Id vaccines would considerably boost the clinical application of this therapy and allow the comparison of the results of different clinical trials.

Recent evidence suggests that the limitations related to the individualized production of Id vaccines may be overcome. In fact, distinct sets of stereotyped Igs have been identified in various B-cell malignancies, suggesting that a...
IGKV3 Proteins as “Off-the-Shelf” Vaccines

Translational Relevance
Cancer vaccines for B-cell lymphomas targeting idiotypic proteins constitute a promising therapeutic strategy. Nevertheless, the individualized production of idiotypic vaccines is still complex, costly, and poorly applicable on a large scale. Moreover, the different manufacturing protocols currently used to produce idiotypic vaccines make it difficult to compare the results of different clinical trials. These limitations may be overcome by the exploitation of the immunogenic properties of distinct clonal immunoglobulin light chains, such as IGKV3-15 and IGKV3-20, which are broadly expressed by different B-cell lymphoproliferations. The ability of IGKV3-based recombinant vaccines to elicit cross-reactive responses against molecularly related light chains provides the rationale to activate a phase I/II study aimed at assessing the safety and efficacy of these vaccines. Achievement of these goals would make available a ready-to-use recombinant vaccine for improved consolidation therapy of low-grade B-cell lymphomas.

much higher frequency of Id sharing exists among patients than appreciated previously. In particular, the molecular characterization of Hepatitis C Virus (HCV)-related lymphomas showed that >70% of these cases preferentially use either IGKV3-20 or IGKV3-15 light chains, with a high degree of homology across different lymphomas (11–14). Similar molecular features have been also found in a proportion of non-HCV-related B-NHLs, including autoimmune-associated lymphoproliferations (13), diffuse large B-cell lymphomas (15), marginal zone B-cell lymphomas (16, 17), follicular lymphomas (18), multiple myeloma (18), and chronic lymphocytic leukemias (18–20). On these grounds, IGKV3-based vaccines could be used in a considerable fraction of patients with different B-cell lymphoproliferations.

This study aimed at characterizing the immunogenic properties of IGKV3-20 and IGKV3-15 proteins with the final goal to provide the rationale for the use of these molecules as “shared” vaccines. We herein show that IGKV3-20-derived peptides selected for HLA-A*0201–restricted cyclin D1–derived peptide binding. The expressed proteins were purified by affinity column and their sequence verified by fingerprinting analysis of trypsin-digested extracts (22). Endotoxin level was <1.0 EU/µg of protein (LAL method).

Cell lines
Lymphoblastoid cell lines (LCL) were generated by in vitro transformation of B cells with the B.95.8 Epstein–Barr virus isolate. The SH9 LCL was established from peripheral blood mononuclear cells (PBMC) of a patient with Hodgkin lymphoma. The DG75 Burkitt’s lymphoma cell line was obtained from DSMZ and confirmed by fingerprinting (Power Plex 1.2; Promega) in April 2011. Cell lines were cultured in RPMI-1640, containing 10% heat-inactivated FBS (Gibco), 2 mmol/L-glutamine, and 100 IU/mL streptomycin, and 100 IU/mL penicillin (Sigma-Aldrich) and maintained at 37°C in a 5% CO2 atmosphere.

Generation and characterization of IGKV3-specific CTLs
Generation of IGKV3- and peptide-specific CTLs was conducted as described (23, 24). After 3 stimulations with protein- or peptide-loaded DCs, CTL cultures were characterized with the following FITC-, PE-, ECD-, PC5-, PC7-labeled antibodies used in a 5-color combination: anti-CD3 (UCHT1, IgG1), anti-CD45RA (2H4LDH11LDB9, IgG1), anti-CD4 (13B8.2, IgG1), anti-CD8 (SFCI21ThyD3, IgG1; Beckman Coulter), anti-CCR7 (3D12, Rat, IgG2b; BD Biosciences PharMingen), anti-CD11a (H111, IgG1), anti-CD44 (IM7, Rat IgG2b), anti-CD49d (9F10, IgG1, k) and anti-CD62L (DREG56, IgG1, k; eBioscience). Mouse FITC- and PE-IgG1 (679.1Mc; Beckman Coulter) and Rat PE-IgG2a (eBRA; eBioscience) were used as isotypic controls. Cytolucimetric analysis was conducted with a Cytomx FC500 and the data analyzed with CXP software (Beckman Coulter). To generate peptide-specific CTL microcultures, dendritic cells (DC) were differentiated from peripheral blood monocytes of HLA-A*0201+ donors and loaded overnight with 25 µg/mL of each of 10 different IGKV3-20–derived peptides selected for HLA-A*0201 binding. The HLA-A*0201–restricted cyclin D1–derived peptide (LNDRRLRA) and the Flu-matrix58–66 peptide served as negative and positive controls, respectively. For each peptide, 30 replicate microcultures were set-up and fed with IL-
Clinical Cancer Research

and using as stimulators (Endogen) according to manufacturer’s instructions. All tests were conducted in triplicate. HLA class I negative controls never exceeded 5 spots/well. Responses were considered significant if >5 IFN-γ-producing cells were detected.

Detection of humoral responses to IGKV3-20 in lymphoma patients

The analysis was carried out using a chemiluminescent ELISA test. Briefly, 96-well microtiter plates were coated overnight with either recombinant IGKV3-20 protein or Tetanus Toxoid (TT, Calbiochem) antigens (2 μg/mL). Plates were evaluated by a computer-assisted ELISpot reader (Eli Expert, A.EL.VIS). The number of spots in negative controls never exceeded 5 spots/well. Responses were considered significant if >5 IFN-γ-producing cells were detected.

T-cell epitope mapping and characterization

Identification of IGKV3-20–derived epitopes was carried out with the iTopia Epitope Discovery System (Beckman Coulter; ref. 26). Briefly, 100 9-mer peptides overlapping by 8 residues spanning the entire length of the protein (108 aa) were screened for their ability to bind 8 HLA class I alleles (A*0101, A*0201, A*0301, A*1101, A*2402, B*0702, B*0801, and B*1501) under optimal conditions (27). The percentage of binding was assessed using a fluorimeter and peptides which bound MHC molecules >20% compared with the reference positive control were selected for analysis of affinity, expressed as ED50 (the concentration at which the peptide is bound to the MHC at 50% maximum binding efficiency). Peptides were also analyzed for off-rate (complex stability) where $T_{\frac{1}{2}}$ represents the time taken for a reduction from optimal binding of 50% after a shift to dissociating conditions (27).

IGKV3-20–specific humoral and T-cell responses in animal models

Six- to 8-week-old female SCID or HHD mice were used according to the national guidelines (28). HHD mice were immunized by subcutaneous (s.c.) injections of KLH-conjugated IGKV3-20 (100 μg) emulsified in incomplete Freund adjuvant (Sigma-Aldrich). Subsequent injections were conducted at day 14, 21, 30, and 45 with 100 μg of KLH-conjugated IGKV3-20 emulsified in incomplete Freund adjuvant. HHD sera were analyzed at day 0 and 30 by ELISA. Ten μg/mL of nonconjugated IGKV3-20 were coated onto a 96-well Maxisorp NUNC-immunoplate (Thermo Scientific) in 0.05M sodium carbonate/bicarbonate buffer pH 9.6 (Sigma-Aldrich), overnight at 4°C. After incubation for 1 hour at RT with 100 μL/well of PBS-10% FBS, plates were incubated for 1 hour at RT with sequential dilutions of mouse sera in PBS-10% FBS (from 1:50 to 1:6400). Negative control was PBS-10% FBS alone and sera at day 0 (1:50 in PBS-0.05% Tween). Finally, 100 μL/well of substrate solution (prepared using SIGMA-Fast OPD tablets) were added for 5 minutes at RT in the dark. Reaction was stopped with 50 μL/well of HCl 3N (Carlo Erba), and plates analyzed at 490 nm using a VictorX4 instrument (Perkin-Elmer). Data were used to generate a titration curve. The same sera used in ELISA test were analyzed for their ability to stain DG75 cells in flow cytometry.

IGKV3-20–specific CTLs were generated from HHD mice showing humoral responses capable of staining DG75 cells cytofluorimetrically. Candidate mice were sacrificed, their splenocytes isolated and cultured (25 × 10^6) with 1 μmol/L IGKV3-20 protein or γ-irradiated (60 Gy) DG75 cells (1 × 10^6) for 4 days. Splenocytes from nonimmunized HHD mice were used as negative controls. At day 4, cells were harvested and CTL cultures positive at the cytotoxicity assay were maintained with appropriate stimulus (either 1 μmol/L protein or 1 × 10^5 γ-irradiated DG75), and tested every 2 weeks to assess their lytic ability. Winn assay was conducted by injecting s.c. 5 × 10^6 DG75 or SH9 cells/animal mixed with either RPMI or donor-derived IGKV3-20–specific CTLs (5 × 10^6/animal), testing 6 animals/group. Mixing was conducted by incubating cells for 5 minutes at 4°C immediately before injection, to rule out T-cell/target interaction before in vivo transfer. Tumor growth was evaluated every 2 to 3 days using a caliper (29).

Results

Ex vivo immunogenicity of IGKV3-20 and IGKV3-15 recombinant proteins

The IGKV3-15 and IGKV3-20 proteins are expressed by a sizeable fraction of B-cell malignancies (Table 1). In particular, IGKV3-20 is used 2 to 3 times more frequently than IGKV3-15. Two representative IGKV3-15 and IGKV3-20 recombinant proteins were used to induce CTL cultures by stimulating PBMCs of healthy donors with protein-pulsed...
autologous DC. Specific CTL lines were easily obtained from 14 donors with either IGKV3-20 (n = 12) or IGKV3-15 (n = 4) proteins (Fig. 1A and Supplementary Table S2). Overall, almost 30% of the cells in the cultures (29.5 ± 5.9%; mean ± SD; n = 10) were CD8+ T cells, most of which (>90%) were effector memory (CCR7−CD45RA−) or terminally-differentiated (CCR7−CD45RA+) T cells (Supplementary Table S3). Notably, these cultures were also composed of a significant proportion of CD4+ T cells (62.76 ± 6.20%; n = 10). All CTL cultures generated with IGKV3-20 or IGKV3-15 showed class I-restricted cytotoxic activity against autologous LCLs pulsed with the immunizing protein (Fig. 1A).

Considering the derivation from antigen-experienced B cells of most lymphomas expressing IGKV3-20 or IGKV3-15, these proteins may have undergone the process of somatic hypermutation and may thus show a certain degree of inter-patient variation in the amino acid sequence. This does not apparently constitute a major limitation because CTLs induced by a prototypic IGKV3-20 light chain (VK3-20b) were also able to specifically kill autologous targets loaded with idiotypic VK proteins of the same subfamily (VK3-20b, Figs. 1B and C) derived from unrelated NHL. These results were obtained in 4 donors with different HLA class I haplotypes (Fig. 1B), thus showing that the CTL responses induced by a “prototypic” IGKV3-20 protein may have a potential immunotherapeutic value also in unrelated patients carrying lymphomas showing the same VK restriction.

**IGKV3 proteins induce cross-reactive CTL responses**

The IGKV3-15 and IGKV3-20 proteins show a sequence homology >80% (Fig. 1D), a biochemical basis for the induction of cross-reactive responses. To address this issue directly, we verified whether IGKV3-15–specific CTLs could kill autologous targets presenting IGKV3-20, and vice versa. As shown in Fig. 1E, IGKV3-15– and IGKV3-20–specific cultures obtained from 3 donors significantly killed, in a class I–restricted fashion, also mismatched targets. Intriguingly, IGKV3-20–induced CTLs killed IGKV3-15–loaded targets with an efficiency comparable to that of matched IGKV3-15–CTLs; only in a single case, IGKV3-20–CTLs showed about a 2-fold higher killing activity against IGKV3-15 targets than matched CTLs (Fig. 1E).

Table 1. Distribution of IGKV3-15 and IGKV3-20 proteins among B-cell malignancies

<table>
<thead>
<tr>
<th>B-cell malignancy</th>
<th>IGKV3-15 N (%)</th>
<th>IGKV3-20 N (%)</th>
<th>IGKV3-15 or IGKV3-20 N (%)</th>
<th>IGKV3 family N (%)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV-related NHL</td>
<td>3/21 (14.3)</td>
<td>12/21 (57.1)</td>
<td>15/21 (71.4)</td>
<td>16/21 (76.2)</td>
<td>10, 13</td>
</tr>
<tr>
<td>Splenic marginal-zone lymphomas</td>
<td>1/31 (3.2)</td>
<td>3/31 (9.7)</td>
<td>4/31 (12.9)</td>
<td>5/31 (16.1)</td>
<td>17</td>
</tr>
<tr>
<td>Sjogren syndrome–associated</td>
<td>2/7 (28.6)</td>
<td>4/7 (57.1)</td>
<td>6/7 (85.7)</td>
<td>6/7 (85.7)</td>
<td>12</td>
</tr>
<tr>
<td>lymphoproliferations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MALT lymphomas</td>
<td>2/18 (11.1)</td>
<td>7/18 (38.9)</td>
<td>9/18 (50)</td>
<td>9/18 (50)</td>
<td>15, 16</td>
</tr>
<tr>
<td>Follicular lymphomas</td>
<td>—</td>
<td>3/47 (6.4)</td>
<td>—</td>
<td>6/47 (12.8)</td>
<td>17</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>4/71 (5.6)</td>
<td>7/71 (9.9)</td>
<td>11/71 (15.5)</td>
<td>11/71 (15.5)</td>
<td>17</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemias</td>
<td>28/614 (4.6)</td>
<td>72/614 (11.7)</td>
<td>100/614 (16.3)</td>
<td>139/614 (22.6)</td>
<td>17–19</td>
</tr>
</tbody>
</table>

Sequencing of IGKV genes expressed by a large panel of B-cell lines allowed the identification of the DG75 BL cell line (HLA-A*0201/6601, B*4101/5001) naturally expressing IGKV3-20, and the SH9 LCL (HLA-A*0201/0101, B*0702/0801) expressing the IGKV3-15 protein. Notably, both these cell lines were killed in an antigen-specific and HLA-A*02–restricted manner by IGKV3-20–specific CTLs obtained from donors single-matched for HLA-A*0201 with target cell lines (Fig. 2). These findings indicate that IGKV3-20 and IGKV3-15 are naturally processed in lymphoid cells and produce “cross-reactive” epitopes.

**IGKV3-specific humoral and CD8+ T-cell responses in lymphoma patients**

The presence of memory T-cell responses specific for IGKV3-20 and IGKV3-15 proteins was investigated in 13 patients with IGK+ HCV-NHLs. A 48-hour ELISPOT assay disclosed low-to-moderate amounts of IFN-γ–producing T cells in the majority of patients (3-98 SFC/100,000 CD8+ T cells), whereas all donors (n = 4) showed low-level responses (<7 SFC/100,000 CD8+ T cells; Fig. 3A). Moreover, specific humoral responses to IGKV3-20 protein were also observed in most of the patients from whom serum was available (n = 11; Supplementary Fig. S1).

**IGKV3-20 CTL epitope mapping and validation**

Using the iTopia assay (26), we identified 21 IGKV3-20 peptides able to bind at least 1 of 8 MHC allele products. Interestingly, although most peptides (n = 18) bound only one allele, the P5, P28, and P97 peptides bound 2 to 3 different alleles (Supplementary Table S4). All peptides were low-to-medium binders, with ED50 ranging from 110 to 255 μmol/L (Supplementary Table S4) and half-times varying from 18 to 135 minutes, similarly to other Id-derived peptides (30).

The ability of HLA-A*0201–binder peptides to elicit specific T-cell responses was assessed by IFN-γ-ELISPOT with purified CD8+ T cells obtained from 3 IGK+ HCV-NHL patients and 2 healthy donors. IFN-γ–producing T cells were found in the majority of patients with lymphoma, with higher responses for most epitopes as compared with healthy donors (15–20 vs. 5–10 SFC/100,000 CD8+ T
cells; Fig. 3B). In addition, epitope-specific CTLs were successfully induced 

\textit{ex vivo} from 6 different donors using each of 10 A’0201-restricted, IGKV3-20–derived peptides (Fig. 3C). Notably, CTLs induced with P20 and P33 peptides were able to kill lymphoma cells expressing either IGKV3-20 (DG75) or IGKV3-15 (SH9) in a HLA-A2–restricted fashion (Fig. 3D).

**Cross-reactivity of CTL responses elicited by IGKV3-20–derived epitopes**

The ability of IGKV3-20–specific CTLs to "cross kill" targets presenting or naturally expressing IGKV3-15 prompted us to verify whether the IGKV3-20–derived epitopes are also shared by other IGK proteins from the IGKV3 as well as from unrelated IGKV families, to better define the
extent of lymphoid tumors potentially treatable with IGKV3-20–based vaccines. Sequences of T-cell epitopes were then aligned against all germ-line IGKV sequences retrieved from the ImMunoGeneTics information system (31). As a conservative rule, only peptides showing only one amino acid change compared with the IGKV3-20 epitopes were considered. The analysis showed that most of the IGKV3-20 epitopes are conserved in several light chains of the IGKV3 family (Supplementary Table S5). Interestingly, 2 of these epitopes (P32 and P33) are shared also by several other IGKV families extensively used among B-cell tumors (Supplementary Table S5). Moreover, the HLA-A alleles restricting these peptides (A*1101 and A*2402 for P32 and A*0201 for P33) would ensure a broad population coverage.

To assess whether the cross-reactivity of IGKV3-20–specific CTLs against IGKV3-15–loaded targets was mediated by the recognition of identical or variant epitopes, 30 independent CTL microcultures, for each of 13 different peptide/donor conditions, were generated either using P20, P32, P33, P46, P47, and P48 peptides. Each peptide-specific culture was tested using both the native and the corresponding IGKV3-15–derived variant peptide epitope as target. Part of peptide-specific microcultures were able to efficiently recognize and kill T2 cells loaded not only with the same native peptide, but also with the variant epitope peptides (Supplementary Fig. S2A and S2B). More interestingly, few cultures showed cell lysis selectively to variant peptides, although no cytotoxicity against the native epitope was observed (Supplementary Fig. S2). Thus, IGKV3-20–specific CTLs recognize both similar and variant epitopes in IGKV3-15, further emphasizing the cross-reactivity of IGKV3-induced responses.

We also analyzed the ability of 2 representative IGKV3-20–derived A*0201 peptides to generate CTLs able to cross-react against 9 epitope variants (2 for P20 and 7 for P33) differing only for 1 amino acid and carried by IGK chains expressed by different B-cell tumors (Supplementary Table S5). Four of these “variant” peptides had a single amino acid substitution at the MHC anchor sites. As shown in Fig. 4A, T-cell lines generated from A*0201 donors with the P20 and P33 peptides specifically recognized and efficiently killed autologous LCLs pulsed with all the epitope variants as well as IGKV3-15+ and IGKV3-20+ lymphoma cell lines (Fig. 4B). Notably, in some instances, the killing of LCLs pulsed with the variant peptides was even higher than that induced by the “native” peptides (Fig. 4A and B). The extent of cytotoxic responses against variant peptides was retained at comparable levels also at low effector:target ratios (1:1) and when LCLs were pulsed with peptide concentrations as low as 1 μg/mL (not shown), thus assuring about the specificity of recognition. All the variant peptides investigated showed a similar or, more frequently, lower predicted binding affinity to A*0201 as compared with the “native” epitopes (Supplementary Table S5). These findings suggest that the IGKV3-20 protein carries natural heteroclytic versions of several CTL epitopes in the IgK proteins broadly expressed among lymphoid malignancies.

**Humoral and cellular responses to IGKV3-20 in mice**

Immunization of HHD mice with KLH-conjugated IGKV3-20 yielded high titers of specific antibodies (Fig. 5A). Sera were also tested for the capacity of staining cytfluorimetrically the IGKV3-20+ DG75 cells. After a first round of 3 immunizations, DG75 cells were not recognized and additional immunizations were required to obtain a detectable staining signal (Fig. 5B). Interestingly, although ELISA Ig titers remained almost constant (not shown), indicating that antibodies to IGKV3-20 had already reached a plateau, repeated immunizations boosted detectable levels of Ig capable of recognizing naturally folded, public epitopes physiologically present on the membrane-mounded protein.

Immunization-induced CTL generation was also exploited in the HHD mouse model, which allows the presentation of epitopes in the HLA-A*0201 context, and hence the generation of mouse CTLs potentially able to recognize human A*0201+ target cells. Splenocytes from IGKV3-20–immunized mice were restimulated in vitro with irradiated DG75 cells and tested 4 days later for lytic activity. As shown in Fig. 5C, these effectors showed a strong IGKV3-20–specific CTL activity. To assess whether the in vitro ability of CTL lines to target and lyse IGKV3+ cells could find an in vivo counterpart in the capacity of restraining tumor growth, SCID mice were injected in one flank with DG75 tumor cells admixed with human IGKV3-20-specific CTLs (ratio 1:1), although the opposite flank was inoculated with tumor cells alone. Control DG75 tumors developed in 100% of injected animals 8 to 9 days after inoculation, and reached the allowed maximal tumor volume in about 15 days. Conversely, at the site where DG75 cells and IGKV3-20–specific CTLs were coinjected, no growth, nor formation of tumor masses occurred over the entire observation period, thus
showing the tumor growth inhibitory activity of IGKV3-20–specific CTLs ($P < 0.001$, $n = 3$; Fig. 5D). Similar findings were observed with the IGKV3-15–SH9 cell line, thus confirming the cross-reactivity of IGKV3-20 CTL responses also in vivo ($P = 0.001$, $n = 3$; Fig. 5E).

**Discussion**

In this study, we have extensively characterized the immunogenic properties of the homologous IGKV3-20 and IGKV3-15 proteins, which can be considered as prototypic “off-the-shelf” vaccines. In fact, these proteins are
collectively expressed by a large fraction of HCV-related NHL (>70%) and by a sizeable proportion of HCV-unrelated lymphoid malignancies (Table 1). Both IGKV3 proteins were shown to easily elicit HLA class I–restricted specific CTL responses \textit{ex vivo} from different donors, thus excluding the existence of “holes” in the TCR repertoire because of central tolerance. These proteins are also naturally immunogenic \textit{in vivo}, as shown by the detection of specific humoral and CD8+ T-cell responses in patients with lymphoma, ruling out also the occurrence of peripheral tolerance/ignorance. Notably, the presence a significant proportion of CD4+ T lymphocytes within the cultures generated with IGKV3-20 and IGKV3-15 is of relevance in the light of the critical role of CD4+ T-cell responses in mediating the vaccine effect.

An ideal “shared” IGKV3 vaccine should elicit CTL responses effective against unrelated lymphomas expressing IGKV3 proteins. This is a relevant issue if we consider that most of NHLs potentially treatable with these vaccines derive from antigen-experienced B cells, whose Id proteins may thus carry somatic mutations possibly affecting immune recognition. Our findings indicate that CTLs induced with a prototypic IGKV3-20 may be effective also against IGKV3-20 proteins derived from different NHLs, supporting the potential immunotherapeutic value of this vaccine for unrelated patients with IGKV3-20+ lymphomas. Furthermore, we also show that CTLs induced by IGKV3-20 or IGKV3-15 elicit mutually cross-reactive responses, being able to efficiently kill target cells presenting or naturally expressing the mismatched IGKV3 protein. Considering the relatively frequent usage of IGKV3-20 and IGKV3-15 among lymphoid malignancies, these findings support a broad applicability of these vaccines. The higher prevalence of IGKV3-20 expression and its slightly higher efficiency in eliciting “cross-reactive” CTL responses indicate that IGKV3-20 is the preferred candidate for vaccination.

The immunogenicity of IGKV3-20 is supported by the identification of 21 different CTL epitopes presented by

Figure 4. A, cross-reactive CTL responses induced by CTL cultures generated from 4 donors with the HLA-A*0201 P20 and P33 IGKV3-20 peptides against 2 and 7 variants of the P20 and P33 epitopes, respectively. Lysis of autologous LCLs loaded with either native peptides (N) or recombinant IGKV3-20 as well as the HLA-A*0201 restriction (cr11.351 mAb), IGKV3-20- LCLs and cyclin D1–derived peptide (Cy D1) loaded LCLs served as negative control (P < 0.02, Student t test). B, lytic activity of CTLs generated from 3 donors with native or variant HLA-A*0201 P20 and P33 peptides against lymphoma cells naturally expressing IGKV3-20 (DG75) or IGKV3-15 (SH9).
common HLA class I alleles. All these peptides were low- to medium binders, consistently with their derivation from a self-protein and with the features of other Id-derived epitopes (30). Memory CD8+ T-cell responses to the majority of HLA-A*0201–restricted IGKV3-20 epitopes were detected in patients with HCV-NHL, indicating that these epitopes are immunogenic in vivo. Moreover, we also showed that CTLs specific for these epitopes can be generated from different A*0201+ donors. Notably, these effectors were able to kill in a HLA-A2–restricted fashion lymphoma cells expressing either IGKV3-20 or IGKV3-15, showing that these shared epitopes are efficiently generated and presented by tumor cells.

Notably, IGKV3-20 carries 3 promiscuous epitopes able to bind 2 or 3 different HLA class I allele products. Given the relatively well-established class I binding motifs for most alleles (32, 33), binding of epitopes across a broad spectrum of HLA class I alleles has been considered the exception rather than the rule (34, 35). Indeed, several CTL epitopes can be presented in the context of more than 1 HLA class I allele product, although this is largely limited to the same HLA supertype (34–37). The 3 IGKV3-20 promiscuous CTL epitopes show binding properties that extend beyond a single HLA supertype, being in this respect similar to viral epitopes (38). Therefore, a broad HLA coverage of the IGKV3-20 vaccine is assured not only by a relatively high number of CTL epitopes presented by common HLA molecules, but also by the promiscuity of distinct epitopes. Notably, IGKV3-20 promiscuous peptides are able to induce specific effectors with similar cytotoxic activity from donors with unrelated HLA alleles (Supplementary Fig. S2C and S2D), a relevant prerequisite for the induction of comparable CTL responses across different HLA backgrounds.
One of the most intriguing results of this study is the demonstration that 2 IGKV3-20–derived epitopes are fully conserved and shared by various IGKV families broadly expressed among lymphomas/leukemias. Moreover, several "variants" of the IGKV3-20–derived epitopes are carried by clonotypic IGKV proteins expressed by different lymphoid tumors. Notably, IGKV3-20–specific CTLs efficiently recognize and kill autologous targets presenting different A*0201-restricted IGKV3-20 "variant" epitopes, often with a higher efficiency as compared with that elicited against the "native" epitopes. This is consistent with the lower predicted affinity showed by some of the "variant" peptides, which carry single amino-acid substitutions at the MHC anchor sites. These findings indicate that the IGKV3-20 protein carries "natural" heteroclitic versions of several CTL epitopes shared among various IGKV families broadly conserved in the native Ig. Our results support this hypothesis and suggest that the IGKV3-20 vaccine may have the additional immunological advantages to be a "shared" vaccine is related to the carrier of a set of peptides naturally selected for heteroclitic substitutions associated with nearly optimal immunogenic features. This set of T-cell epitopes potentially covers a high proportion of IGKV-restricted B-cell tumors, as at least 1 IGKV3-20 epitope can be found in several light chains from different IGKV families. Moreover, IGKV3-20 also contains promiscuous epitopes, thus assuring a broad HLA coverage. On the whole, these data provide the rationale to activate a phase I/II study aimed at assessing the safety and efficacy of the IGKV3-20 vaccine for patients with lymphomas expressing molecularly correlated Id proteins. Achievement of these goals would make available a ready-to-use recombinant vaccine for improved consolidation therapy of low-grade B-cell lymphomas.

Disclosure of Potential Conflicts of Interest
R. Dolcetti is a consultant/advisory board member of Areta Int. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions
Conception and design: M. Guidoboni, V.D. Re, R. Mortarini, A. Rosato, A. Anichini, R. Dolcetti
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D. Martorelli, V.D. Re, E. Muraro, R. Turrini, A. Merlo, L. Romagnoli, M. Spina, M. Mazzuccato, A. Rosato
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D. Martorelli, M. Guidoboni, V.D. Re, R. Turrini, A. Merlo, R. Mortarini, A. Rosato, A. Anichini
Writing, review, and/or revision of the manuscript: D. Martorelli, M. Guidoboni, V.D. Re, R. Turrini, A. Merlo, M. Spina, R. Mortarini, A. Carbone, A. Rosato, A. Anichini, R. Dolcetti
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Martorelli, V.D. Re, E. Pasini, L. Caggiari, A. Rosato, R. Dolcetti
Study supervision: V.D. Re, A. Rosato, R. Dolcetti

Acknowledgments
The authors thank T. Ooka (Université Claude Bernard Lyon-1, France) for the kind gift of recombinant p29 BARF1 protein, A. Molla and C. Veggetti (Fondazione IRCCS, INT Milan) for technical support, and Miss S. Colussi (CRO-IRCCS, Aviano) for the editing.
Grant Support

The study was supported by grants from the European Community (FP6 037874), the Italian Ministry of Health [AIRC–], the Associazione Italiana per la Ricerca sul Cancro (to R. Dolcetti, A. Anichini, R. Morzarini), and the Fondazione Federica per la Vita. Elisa Pasini is a FIRC fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 5, 2012; revised May 22, 2012; accepted May 31, 2012; published OnlineFirst June 15, 2012.

References

IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas

Debora Martorelli, Massimo Guidoboni, Valli De Re, et al.


Updated version | Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-0763

Supplementary Material | Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2012/06/15/1078-0432.CCR-12-0763.DC1

Cited articles | This article cites 45 articles, 21 of which you can access for free at: http://clincancerres.aacrjournals.org/content/18/15/4080.full#ref-list-1

Citing articles | This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/18/15/4080.full#related-urls

E-mail alerts | Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions | To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/18/15/4080. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.